The present disclosure provides methods for synthesizing cantharidin and cantharidin derivatives.

The present disclosure provides methods for synthesizing cantharidin and cantharidin derivatives.

The present disclosure provides methods for synthesizing cantharidin and cantharidin derivatives.

The present disclosure provides methods for synthesizing cantharidin and cantharidin derivatives.

Compounds of formula (I) are useful as LRRK2 kinase inhibitors.

##STR00001##

The present disclosure provides methods for synthesizing cantharidin and cantharidin derivatives.

The present disclosure provides methods for synthesizing cantharidin and cantharidin derivatives.

Conformationally restricted, spatially defined 12-30 membered macrocyclic ring systems of type (I) are constituted by three distinct building blocks: an aromatic template a, a conformation modulator b and a spacer moiety c as detailed in the description and the claims. Macrocycles of type (I) are readily manufactured by parallel synthesis or combinatorial chemistry. They are designed to interact with specific biological targets. In particular, they show agonistic or antagonistic activity on the motilin receptor (MR receptor), on the serotonin receptor of subtype 5-HT.sub.2B (5-HT.sub.2B receptor), and on the prostaglandin F2receptor (FP receptor). They are thus potentially useful for the treatment of hypomotility disorders of the gastrointestinal tract such as diabetic gastroparesis and constipation type irritable bowl syndrome; of CNS related diseases like migraine, schizophrenia, psychosis or depression; of ocular hypertension such as associated with glaucoma and preterm labour. ##STR00001##

Conformationally restricted, spatially defined 12-30 membered macrocyclic ring systems of type (I) are constituted by three distinct building blocks: an aromatic template a, a conformation modulator b and a spacer moiety c as detailed in the description and the claims. Macrocycles of type (I) are readily manufactured by parallel synthesis or combinatorial chemistry. They are designed to interact with specific biological targets. In particular, they show agonistic or antagonistic activity on the motilin receptor (MR receptor), on the serotonin receptor of subtype 5-HT.sub.2B (5-HT.sub.2B receptor), and on the prostaglandin F2receptor (FP receptor). They are thus potentially useful for the treatment of hypomotility disorders of the gastrointestinal tract such as diabetic gastroparesis and constipation type irritable bowl syndrome; of CNS related diseases like migraine, schizophrenia, psychosis or depression; of ocular hypertension such as associated with glaucoma and preterm labour. ##STR00001##

An abstract heading is required. Please delete this heading section if it is not applicable to your application. For more information regarding the headings of the abstract, please see MPEP 608.01(b).